IMMUNITYBIO, INC. Marketable Securities (Current)
IMMUNITYBIO, INC. (IBRX) had Marketable Securities (Current) of $281.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-04
- 2026-06-30: Marketable Securities, Current $281.70M.
- 2026-03-31: Marketable Securities, Current $175.69M.
- 2025-12-31: Marketable Securities, Current $154.48M.
- 2025-09-30: Marketable Securities, Current $197.57M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $281.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $175.69M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $154.48M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $197.57M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $16.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $931.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $6.38M 10-K · filed 2026-02-23 |
| 2024-09-30 | $18.40M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $87.88M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $37.46M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.01M 10-K · filed 2025-03-03 |
| 2023-09-30 | $11.83M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.45M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.79M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.54M 10-K · filed 2024-03-19 |
| 2022-09-30 | $6.90M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $21.04M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $155.95M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $136.01M 10-K · filed 2023-03-01 |
| 2021-09-30 | $15.85M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $19.97M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $38.59M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $61.15M 10-K · filed 2022-03-01 |
| 2017-12-31 | $104.28M 10-K · filed 2018-03-12 |
| 2017-09-30 | $131.35M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $136.47M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $177.37M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $190.84M 10-K · filed 2018-03-12 |
| 2016-09-30 | $177.85M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $175.54M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $158.51M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $118.31M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |